Cytosorbents (NASDAQ:CTSO) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Cytosorbents (NASDAQ:CTSO) released its quarterly earnings results on Wednesday. The medical research company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.04), Zacks reports. The business had revenue of $9.23 million for the quarter, compared to the consensus estimate of $9.21 million. Cytosorbents had a negative return on equity of 131.86% and a negative net margin of 22.12%.

Here are the key takeaways from Cytosorbents’ conference call:

• Full‑year revenue was up 4% to $37.1M with record core product sales, driven by double‑digit growth in international direct sales (+13%) and distributor sales (+11.4%) but partially offset by a 10% decline in Germany due to a commercial restructuring.
• Gross margins strengthened to 71% for the year and 74% in Q4, driven by manufacturing efficiencies that support improved profitability and lower production spend going into 2026.
• DrugSorb‑ATR faces regulatory uncertainty after an initial de novo denial, but the appeal found no safety concerns, FDA discussions are ongoing for a targeted resubmission, and the STAR‑T randomized trial was published showing safety and reduced bleeding.
• Management has reduced costs (including a Q4 restructuring), improved operating and adjusted EBITDA losses, and expects operating cash‑flow breakeven in the second half of 2026 while carrying $7.8M in cash as of year‑end.
• Commercial innovations—>100 placements of the standalone PuriFi pump and the new HotSwap cartridge‑exchange—are intended to expand access, enable earlier intervention, and drive incremental recurring disposable cartridge usage.

Cytosorbents Price Performance

NASDAQ CTSO opened at $0.59 on Monday. The stock has a market cap of $37.24 million, a PE ratio of -4.56 and a beta of 1.36. The stock’s 50 day moving average is $0.69 and its 200 day moving average is $0.75. Cytosorbents has a 12 month low of $0.50 and a 12 month high of $1.39. The company has a current ratio of 2.11, a quick ratio of 1.71 and a debt-to-equity ratio of 1.61.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on CTSO. Weiss Ratings restated a “sell (e+)” rating on shares of Cytosorbents in a report on Friday, January 9th. D. Boral Capital reissued a “buy” rating and issued a $10.00 price target on shares of Cytosorbents in a research report on Thursday. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $5.38.

Hedge Funds Weigh In On Cytosorbents

A number of hedge funds and other institutional investors have recently modified their holdings of CTSO. Avenir Corp lifted its stake in Cytosorbents by 2.9% during the 4th quarter. Avenir Corp now owns 5,230,099 shares of the medical research company’s stock worth $3,343,000 after acquiring an additional 147,261 shares in the last quarter. CIBC Bancorp USA Inc. acquired a new stake in shares of Cytosorbents in the third quarter valued at approximately $161,000. Citadel Advisors LLC grew its position in shares of Cytosorbents by 127.3% during the third quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock worth $61,000 after acquiring an additional 36,790 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Cytosorbents by 3.7% during the third quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock worth $2,059,000 after buying an additional 79,535 shares during the period. Finally, Goldman Sachs Group Inc. raised its stake in shares of Cytosorbents by 149.2% during the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock worth $63,000 after purchasing an additional 37,519 shares during the last quarter. 32.87% of the stock is currently owned by institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.